The glycoprotein 100 (gp100) is reported to be expressed in 63–90% of melanomas [6, 7] and has long been of interest as a potential therapeutic target, leading to numerous targeted therapy trials including gp100-targeted vaccines and adoptive cell transfer. Here, PMEL is linked to melanoma.